Drugs / ortataxel
ortataxel
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01989884 | Nov 2013 → Dec 2015 | adult glioblastoma | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 2 | NCT00044525 | Apr 2002 → Feb 2004 | breast cancer | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00054314 | Mar 2002 → Apr 2003 | lung cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00044551 | Feb 2002 → Jul 2003 | non-Hodgkin lymphoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00039156 | Jan 2002 → ? | lymphoma | Theradex | Unknown | No outcome recorded |
| Phase 2 | NCT00044564 | Dec 2001 → Jan 2003 | renal cell carcinoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00044538 | Dec 2001 → Jun 2004 | non-small cell lung carcinoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00039169 | Dec 2001 → ? | kidney cancer | Theradex | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ortataxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00039156 ↗ |
| Known as | Bay 59-8862 | “Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma” NCT00044551 ↗ |
| Known as | IDN 5109 | ChEMBL registry synonym — accepted as the source's own label CHEMBL382300 ↗ |
| Known as | SB-T 101131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL382300 ↗ |
| Modality | Small molecule | “BAY59-8862 (Cytotoxic Taxane)” NCT00044538 ↗ |
| Route | Intravenous | “1 h intravenous infusion every 3 weeks” NCT00044525 ↗ |